- email:professionalcustserv@informa.com
- phone:+44 (0) 20 7017 5503
Pharmaceutical Law Summer School conference 2010 provides the essential route to a comprehensive update on the key legal challenges affecting the pharmaceutical and medical devices industries
What is unique about the Pharmaceutical Law Summer School 2010?
The Pharmaceutical Law Summer School provides the perfect opportunity for those new to the industry to gain an all-encompassing introduction to the legal and commercial challenges faced in the pharmaceutical sector in a relaxed and informal atmosphere. For those who are more familiar with the sector, the course serves as a vital refresher on the topics that you may not encounter every day but need to keep abreast of.
Who should attend?
- Private practitioners with pharma clients
- In-house lawyers
- Regulatory managers
- Commercial managers
- Labelling mangers
- Compliance managers
- Export managers
- Pricing managers
Meet the Summer School's panel of expert speakers
- Harald Mische, Case Handler,Pharma Sector Enquiry, DG Competition,European Commission
- Dr. Carol Longson, Health Technology Evaluation Centre Director, National Institute for
Clinical Excellence (NICE) - Bryan Black, Senior Legal Counsel, Novartis
- Jerry Temko, Senior Vice President & General Counsel, Astellas
- Peter Bogaert, Partner, Covington & Burling
- Sally Shorthose, Partner, Bird & Bird
- Nick Beckett, Head of IP & Life Sciences, CMS Cameron McKenna
- Ian Dodds-Smith, Head of European Product Liability Group, Arnold & Porter
- Bert Oosting, Partner, Hogan Lovells
- Liz Fuller, Director, Life Sciences Regulatory (US qualified), Wragge & Co
- James Killick, Partner, White & Case
- Michael Gavey, Managing Associate, Simmons & Simmons
And more! Check out the Pharmaceutical Law Summer School brochure, for the full speaker list
What will you learn at this event?
- Future of collaborations in the pharmaceutical market
- Latest European patent case law relating the pharmaceutical and medical device products
- New Customs Regulations for combating counterfeit products
- Key regulatory concerns relating to paediatric incentives, biosimiliars, data exclusivity and orphan medicines
- Impact of the new US Health Reform Act
- Review new anti-bribery regulations
- Resolve pricing and reimbursement challenges across Europe
- New proposals for reform to clinical trials regulations
- Update on marketing and promotion trends and strategies
- React appropriately to product liability concerns
- Successfully challenge decisions of NICE, EMEA and MHRA
Media Partners
Download Latest Information Now
(updated 28 July 2010)
Past reviews
"Interesting and useful topics, competent speakers, overall successful and satisfying"
